Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Metastatic
How do you approach treatment of metastatic breast cancer in patients where PIK3CA mutation was detected after progression on both Fulvestrant alone and AI + CDK4/6 inhibitors?
Related Questions
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
How will you sequence Dato-DXd among available therapies for HR positive, HER2-0 metastatic breast cancer?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
What factors should be considered when deciding between datopotamab deruxtecan and sacituzumab govitecan for a patient with metastatic breast cancer?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
What are your top takeaways in Breast Cancer from ESMO 2024?
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
What supportive care measures do you prioritize to manage or prevent toxicity in patients receiving Dato-DXd?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
